Dean Moss BSc, MPhil, PhD (UQ), GAICD

Chief Executive Officer 

A UQ alumnus, Dean Moss has 30 years’ experience in science, academia, business, management and commercialisation in Australia, USA and the UK.

He has been managing director or senior business development executive of several health and biotech companies worldwide, including Agen Biomedical, Launch Diagnostics, AMRAD ICT, AMRAD Biotech, and United Drug.  He established his own start-up business in the UK, York Medical Technologies.  Prior to moving into the commercial world, Dean was principal R&D scientist at Agen Biomedical. He also worked as an NHMRC research scientist at the Princess Alexandra Hospital, the Royal Brisbane Hospital and the Queensland Institute of Medical Research. He is a recipient of the Campion-Ma-Playoust Memorial Award for Medical Research.  Dean is a board member of several Australian companies and was a member of the investment committee of the pre-seed venture funds Uniseed, the Medical Research Commercialisation Fund and the New Zealand Government’s KiwiNet.  He is a current member of the NHMRC Health Innovation Advisory Committee. He has contributed to raising over $100m in venture capital investment.

Rob Hewitt BA (Hons), ACA

Chief Financial Officer

Maintaining UniQuest’s position as one of Australia’s largest and most successful university technology transfer companies, with group revenues exceeding A$50 million, adds another dimension to Rob's already multi-faceted career. 

Originally from the UK, where he studied to become a Chartered Accountant and completed a BA (Honours) in Modern Languages, Rob spent five years with Deloitte Touche Tohmatsu as a Chartered Accountant and Audit Senior. He also honed his technical acumen whilst holding senior financial management positions in organisations operating in a range of industries, including textiles, building materials, cleantech, and private equity. As CFO he draws on his experience in due diligence, acquisitions, integration and capital raising to produce the kind of robust financial intelligence that UniQuest needs to develop positive growth strategies, while ensuring the day-to-day financial processes provide smart and reliable support for that growth.

Mark Ashton BSc (Hons), PhD

Executive Director, Intellectual Property Commercialisation

Dr Mark Ashton joined UniQuest in 2010 and is currently the Executive Director of Intellectual Property Commercialisation.  Prior to this he was the Manager of Innovation and Commercial Development for The Institute for Molecular Bioscience and Health Sciences at The University of Queensland. Before joining UniQuest Dr Ashton was the Executive Vice President, Business Development at the international biotech, Evotec AG, a company that focuses on drug discovery alliances and development partnerships with the pharmaceutical and biotech industry.  Prior to leading the business development group at Evotec, Dr Ashton was President, Discovery Services at Evotec, responsible for the company’s Drug Discovery division, a division that carried out projects involving high throughput screening, parallel synthesis and medicinal chemistry to pre-clinical development. Dr Ashton has worked within the biotech and pharmaceutical industry since the early 1990’s and has both operational and commercial experience of a wide range of life science projects. He has worked with most of the major pharmaceutical companies and a number of biotech companies around the world negotiating agreements totalling in excess of $100M. Dr Ashton is the author and co-author of a number of peer reviewed scientific publications and patents including new chemical entities that have progressed to human clinical trials. He has a PhD in chemistry having worked on a medicinal chemistry focussed project sponsored by an international pharmaceutical company.